Literature DB >> 861145

In vivo cell synchrony in the L1210 mouse leukaemia studied with 5-fluorouracil or 5-fluorouracil followed by cold thymidine infusion.

R S Camplejohn, B Schultze, W Maurer.   

Abstract

[3H]-TdR and [3]-udR labelling indices and mitotic indices were followed in tumour-bearing mice after application of either 5-fluorouracil (FU) alone or of FU followed by cold TdR infusion. With FU alone, accumulation of cells at the beginning of S was found, but there was no indication of a synchronous passage of the accumulated cells further round the cycle. When FU injection was followed by cold TdR infusion, a synchronous passage of the accumulated cells through the cycle was observed. However, there was a large variation in the response of individual mice to this treatment.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 861145      PMCID: PMC2025495          DOI: 10.1038/bjc.1977.88

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  FOUR-FACTOR MODEL ANALYSIS OF THYMIDINE INCORPORATION INTO MOUSE DNA AND THE MECHANISM OF RADIATION EFFECTS.

Authors:  P A STEWART; H QUASTLER; M R SKOUGAARD; D R WIMBER; M F WOLFSBERG; C A PERROTTA; B FERBEL; M CARLOUGH
Journal:  Radiat Res       Date:  1965-04       Impact factor: 2.841

2.  Studies on fluorinated pyrimidines. XIII. Inhibition of thymidylate synthetase.

Authors:  K U HARTMANN; C HEIDELBERGER
Journal:  J Biol Chem       Date:  1961-11       Impact factor: 5.157

3.  Studies on unbalanced growth in tissue culture. I. Induction and consequences of thymidine deficiency.

Authors:  R R RUECKERT; G C MUELLER
Journal:  Cancer Res       Date:  1960-12       Impact factor: 12.701

4.  Growth inhibition of a human tumor cell strain by 5-fluoro-2-deoxyuridine: time parameters for subsequent reversal by thymidine.

Authors:  M L EIDINOFF; M A RICH
Journal:  Cancer Res       Date:  1959-06       Impact factor: 12.701

5.  Studies on fluorinated pyrimidines. XI. In vitro studies on tumor resistance.

Authors:  C HEIDELBERGER; G KALDOR; K L MUKHERJEE; P B DANNEBERG
Journal:  Cancer Res       Date:  1960-07       Impact factor: 12.701

6.  Growth inhibition of a human tumor cell strain by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine; reversal studies.

Authors:  M A RICH; J L BOLAFFI; J E KNOLL; L CHEONG; M L EIDINOFF
Journal:  Cancer Res       Date:  1958-07       Impact factor: 12.701

7.  Blood thymidine level and iododeoxyuridine incorporation and reutilization in DNA in mice given long-acting thymidine pellets.

Authors:  D J Lee; W Prensky; G Krause; W L Hughes
Journal:  Cancer Res       Date:  1976-12       Impact factor: 12.701

8.  Correlation of 5-fluorouracil (NSC-19893) distribution in rodents with toxicity and chemotherapy in man.

Authors:  R H Liss; M Chadwick
Journal:  Cancer Chemother Rep       Date:  1974 Nov-Dec

9.  On the mechanism of the lethal action of 5-fluorouracil on mouse L cells.

Authors:  H Madoc-Jones; W R Bruce
Journal:  Cancer Res       Date:  1968-10       Impact factor: 12.701

10.  Studies on fluorinated pyrimidines. III. The metabolism of 5-fluorouracil-2-C14 and 5-fluoroorotic-2-C14 acid in vivo.

Authors:  N K CHAUDHURI; B J MONTAG; C HEIDELBERGER
Journal:  Cancer Res       Date:  1958-04       Impact factor: 12.701

View more
  3 in total

1.  Comparing cell kinetic studies of the effect of ftorafur and 5-fluorouracil on the L 1210 ascites tumor.

Authors:  B Schultze; W Jellinghaus; G Weis; V Müller; W Maurer
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

2.  The action of 5-fluorouracil on human HT29 colon cancer cells grown in SCID mice: mitosis, apoptosis and cell differentiation.

Authors:  R Sharma; E Adam; U Schumacher
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Evaluation of single-agent therapy in human colorectal tumour xenografts.

Authors:  P J Houghton; J A Houghton
Journal:  Br J Cancer       Date:  1978-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.